Ohr Pharmaceuticals, Inc. (OHRP) insider have most recently took part in a trading activity. On Apr 10, 2017 Hirschman Orin, Director bought 171,429 shares having total worth of $120,000 at the price of $0.7 per share, following the transaction a total of 1,816,377 shares owned by Hirschman Orin.
Furthermore, over the past 12 months , the stock was traded 6 times by insiders. an employee of the company was the buyer in 6 instances.
Shares of Ohr Pharmaceuticals, Inc. (OHRP) traded down 4.26% on Dec 5, 2017, hitting $1.35. 3,423,257 shares of the company’s stock traded hands. Ohr Pharmaceuticals, Inc. has a 52 week low of $0.57 and a 52 week high of $3.75. The company’s market cap is $90 million.
Ohr Pharmaceuticals, Inc. (OHRP) last announced its earnings results on Aug 8, 2017. The company reported -0.07 earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted -0.24 earnings per share.
|earnings per share||-0.07||-0.21||-0.21||-0.21||-0.24||-0.17||-0.20||-0.13||-0.11||-0.12|
Ohr Pharmaceutical, Inc., a Delaware corporation that is organized on August 4, 2009, as successor to, BBM Holdings, Inc., pursuant to a reincorporation merger. The Company is a biotechnology rollup Company focused on development of the Company’s previously acquired compounds. The Company is focused on the development of its two later stage lead products, OHR/AVR118 for the treatment of cancer cachexia (multi-symptom wasting disorder), and Squalamine for the treatment of the wet form of age-related macular degeneration using an eye drop formulation. The Company acquired OHR/AVR118 in a secured party sale and Squalamine from the Genaera Liquidating Trust as part of the Company’s previous strategy to create a rollup of undervalued biotechnology companies and assets. Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, that counteracts not only Vascular Endothelial Growth Factor but also other angiogenic growth factors including Platelet Derived Growth Factor (“PDGF”) and basic Fibroblast Growth Factor. On March 19, 2009, the Company acquired in a secured party sale all the patents, related intellectual property, clinical data and other assets related to AVR118 (also known now as OHR/AVR118). OHR/AVR118 is in an ongoing Phase II trial for the treatment of cachexia. OHR/AVR118 is a novel immunomodulator with a singular chemical structure that is terminally sterilized and endotoxin-free. The compound is composed of two small peptides, Peptide A, which is 31 amino acids long, and Peptide B, that is 21 amino acids long. Peptide B is unique in that the dinucleotide, diadenosine, is covalently attached to serine at position 18 through a phosphodiester bond. OHR/AVR118 is quite stable and has a favorable safety profile both in animal toxicity studies and in human clinical trials. In December 2010, the Company opened a new clinical site for its ongoing Phase II clinical trial to investigate the efficacy of OHR/AVR118 for the treatment of cancer cachexia at the Ottawa Hospital Cancer Centre. The Company is subject to extensive regulation by federal, state and local government authorities, including the FDA.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018